Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
6.24
0.00
(0.00%)
At close: March 12 at 8:55:34 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | 702.6k | 2.26M | 7.32M | 39.39M |
| Low Estimate | -- | -- | 1.9M | 25M |
| High Estimate | 2.51M | 5M | 12.57M | 50.95M |
| Year Ago Sales | -- | -- | -- | 7.32M |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 438.12% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 41ON.SG | -- | -- | -- | -- |
| S&P 500 | 16.04% | 7.30% | 10.63% | 14.23% |
Upgrades & Downgrades
| Maintains | Ascendiant Capital: Buy to Buy | 2/24/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/18/2025 |
| Maintains | Chardan Capital: Neutral to Neutral | 2/18/2025 |
| Reiterates | Guggenheim: Buy to Buy | 1/17/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/17/2025 |
| Downgrade | Chardan Capital: Buy to Neutral | 12/2/2024 |
Related Tickers
LYRA Lyra Therapeutics, Inc.
0.1882
+0.97%
AGE
EYPT EyePoint Pharmaceuticals, Inc.
6.82
+3.65%
DARE Daré Bioscience, Inc.
3.0300
-0.66%
XFOR X4 Pharmaceuticals, Inc.
0.3751
+1.93%
VERU Veru Inc.
0.5282
+0.63%
MIRM Mirum Pharmaceuticals, Inc.
43.42
-2.73%
LQDA Liquidia Corporation
14.86
-4.31%
ATNM Actinium Pharmaceuticals, Inc.
1.1400
-0.87%
SPRB Spruce Biosciences, Inc.
0.3594
+0.06%